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Developing primary palliative care
Continuity of care is paramount but
needs to be tailored individually
Editor—Riley suggests that completion of a
form detailing palliative care management
should be mandatory for general practition-
ers.1 I have spent a great deal of time
promoting palliative medicine in primary
care, with variable success. Much depends
on the individual practitioner’s experience
and interest, which probably accounts for
the variable success of handover forms to
communicate with out of hours services.
Making this a compulsory part of
general practice might bring all practice to
the same level. But the initial answer to the
question, “Would I be surprised if my patient
died in the next 12 months?” would then
make the difference. Cynical practitioners
would probably answer no for nearly all of
their patients, for the longer you practise the
less often you are surprised.
But, in truth, for many patients in
general practice the answer to this question
would be no: many elderly patients who live
in nursing or residential homes, nearly all
patients with chronic disease, including
heart disease, chronic obstructive pulmo-
nary disease, neurological disease, and so
on. The workload in handing these patients
over to the out of hours service would be
huge, more so for the out of hours service
than the individual practice.
Continuity of care for patients who most
need it is paramount, including all those
with chronic disease. However, more sophis-
ticated systems are needed to meet patient
needs: perhaps different systems for differ-
ent diseases, possibly different systems for
each stage of a disease.Whatever the system,
it must meet the needs of the individual
patient. This entails dialogue between
primary care (including out of hours),
secondary care, and tertiary care to thrash
out the detail.
Paul A Fox general practitioner
Stanley Health Centre, Wakefield WF3 4BH
PAFoxy@aol.com
Competing interests: None declared.
1 Riley J. Developing primary palliative care. BMJ 2005;
330:42. (1 January.)
Primary palliative care services must be
better funded by both day and night
Editor—Guthrie’s response to our editorial
of 6 November on developing primary
palliative care is helpful in pointing out that
the new out of hours organisations are now
responsible for three quarters of the week’s
on call hours, while primary care teams
working during the day are responsible for
only a quarter.1 This of course means that
general practitioners and district nurses
working out of hours will often attend
people dying at home.
Unfortunately such busy organisations
are often extremely stretched to deal with
the diverse out of hours workload, and hand
over forms for identifying patients receiving
palliative care who could deteriorate in the
short term are in our experience rarely in
place. Progress is being made by some prac-
tices which routinely notify NHS24 in Scot-
land or NHS Direct in England of such
patients, as recommended, for instance, in
the gold standards framework.2
We do not yet know what effect the new
call centre triaging and accompanying out
of hours arrangements will have on helping
patients to die at home if they so wish. Care
by call centres can be problematic and
perceived as impersonal.3 This underscores
the urgent need to develop plans for provid-
ing 24 hour care for dying people.
As out of hours services continue to
evolve, the attempt to meet the last wishes of
patients, many of whom would like to die at
home if they could, must not be lost sight of.
This means, as Guthrie highlights, that more
community nurses and social support need
to be available out of hours. Ways of
targeting additional support at home for
those with particularly complex needs
should be explored, with community provid-
ers being encouraged to make greater use of
the out of hours advice available from
specialist palliative care services. Otherwise,
as Levack et al suggest,4 only those with the
fewest symptoms and greatest personal
resources will be able to die at home.5
Scott A Murray clinical reader
Scott.Murray@ed.ac.uk
Kirsty Boyd honorary senior lecturer
Aziz Sheikh professor of primary care research and
development
Primary Palliative Care Research Group, Division
of Community Health Sciences: General Practice
Section, University of Edinburgh, Edinburgh
EH8 9DX
Competing interests: None declared.
1 Guthrie CI. Developing primary palliative care. BMJ
2005;330:42. (1 January.)
2 Thomas K. Caring for the dying at home. Companions on a
journey. Oxford: Radcliffe Medical Press, 2003.
3 Douglas D. Out of hours cover. BMJ 2005;330:263.
4 Levack P, Dryden H, Paterson F. Developing primary
palliative care. BMJ 2005;330:42-3. (1 January.)
5 Higginson IJ, Jarman B, Astin P, Dolan S. Do social factors
affect where patients die: an analysis of 10 years of cancer
deaths in England. J Pub Health Med 1999;21:22-8.
Specialist palliative care in
dementia
Patients with dementia are unable to
access appropriate palliative care
Editor—Hughes et al suggest that special-
ised units with outreach and liaison are
needed for palliative care of patients with
dementia.1 The United States has taken a
much more holistic approach than the
United Kingdom in this area. Although sev-
eral papers have been published over the
past few years that highlight the need for
palliative care for such patients,2 3 little more
than lip service is paid to this group of
patients. In our experience, even if patients
with dementia develop advanced cancer
they are seldom admitted to specialist pallia-
tive care units, and palliative care teams are
only too ready to declare such patients as
having no specialist needs or not being
appropriate for their service.
Evidence shows that where psychiatry
and palliative care teams collaborate well,
appropriate palliative care can be delivered
to patients with advanced dementia wher-
ever they may be located.4 The need for
bereavement care for relatives where social
death occurs many months or years before
the physical death must also be included.
We advocate Hughes et al’s suggestion
that through outreach and liaison, palliative
care for people with dementia can be deliv-
ered in the community, including in nursing
and residential homes. Palliative care serv-
ices need to look beyond cancer. Patients
with dementia and their families have a high
symptom burden and all too often are not
offered or provided with the care they
require.
Mari Lloyd-Williams professor
Division of Primary Care, School of Population,
Community and Behavioural Sciences, University
of Liverpool, Liverpool L69 3GB
mlw@liverpool.ac.uk
Sheila Payne professor
School of Nursing, University of Sheffield, Sheffield
S3 7ND
Mick Dennis senior lecturer
Academic Department of Psychiatry for the Elderly,
Leicester General Hospital, Leicester LE6 5PQ
Competing interests: None declared.
1 Hughes JC, Robinson L, Volicer L. Specialist palliative care
in dementia. BMJ 2005;330:57-8. (8 January.)
Details of the two other authors are on
bmj.com
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2 Field D, Addington-Hall J. Extending specialist palliative
care to all? Soc Sci Med 1999;48:1271-80.
3 Lloyd-Williams M. An audit of palliative care in dementia.
Eur J Cancer Care 1996;5:53-5.
4 Lloyd-Williams M, Payne S. Can multidisciplinary guide-
lines improve the palliation of symptoms in the terminal
phase of dementia? Int J Palliat Nurs 2002;8:370-6.
Home based palliative care is important
in developing countries . . .
Editor—The issues raised by Hughes et al
are particularly relevant to dementia care in
settings with limited resources.1 Home based
interventions based on principles of pallia-
tive care can provide help to people with
dementia in low income countries. But con-
trol of symptoms can prove to be difficult
when behavioural and psychological symp-
toms of dementia are present. Unless these
symptoms are identified, caregivers could
misinterpret them as deliberate misbehav-
iour.2 Incontinence of bowel and bladder
and impairment in other activities of daily
living also need special attention.
Broadening the scope of palliative care
services to meet the needs of people with
dementia would be a welcome step, particu-
larly in developing regions of the world.
India’s 10/66 dementia research group has
developed a community based intervention
programme that uses trained community
health workers to identify people with
dementia and deliver simple community
based interventions in the community.3 This
training programme takes into considera-
tion the specific needs of dementia care
while adhering to the general principles of
palliative care.
Shaji K Sivaraman assistant professor of psychiatry
Medical College, Thrissur-680596, India
shajiks@vsnl.com
Competing interests: None declared.
1 Hughes JC, Robinson L, Volicer L. Specialist palliative care
in dementia. BMJ 2005;330:57-8. (8 January.)
2 Shaji KS, Smitha K, Praveen Lal K, Prince MJ. Caregivers
of patients with Alzheimer’s disease: a qualitative study
from the Indian 10/66 dementia research network Int J
Geriatr Psychiatry 2003;18:1-6
3 Shaji KS, Arun Kishore NR, Praveen Lal K, Prince MJ.
Revealing a hidden problem. An evaluation of a
community dementia case-finding program from the
Indian 10/66 Dementia Research Network. Int J Geriatr
Psychiatry 2002;17:222-5.
. . . and hope for terminal care at home is
needed in developed countries
Editor—Good quality care for advanced
dementia is right and laudable and should
be supported. However, we echo the view of
Sivaraman (above) that home based pallia-
tive care of dementia is important and badly
needed in the developed world as well as the
developing world. We think that the meth-
ods required will also be quite different for
cancer care.
We have been developing and pioneer-
ing skills around managing people with
advanced dementia at home for several
years. This is a welcome initiative for carers
and has produced some excellent feedback
from carers and also good observational
data for patients. The skills required are
diverse and certainly bear little resemblance
to any one discipline. Antipsychotic and
antidepressant drugs remain important, but
physical care, aids, mobility, bowel care, pres-
sure care, and other symptom control are
essential components.
The assumption in the editorial by
Hughes et al that pain relief is central is wor-
rying.1 This seems to be simple transference
of the issue of pain in cancer care. We have
seen severely ill and behaviourally disturbed
patients with dementia nearly die from low
doses of opiates, and pain relief may not
necessarily be required in such cases very
often. Palliative care teams have helped in
the work we have been doing, but not often
in a central way.
We would therefore caution against
translating too many of the lessons of cancer
care into dementia care. A strong similarity
with cancer care should be the opportunity
to think about terminal care occurring at
home when possible. However, the situa-
tions are not the same, and the expertise
required for the care of advanced dementia
has several aspects making it substantially
different from cancer care.
Adrian Treloar senior lecturer in old age psychiatry
Memorial Hospital, London SE18 3RZ
adrian.treloar@oxleas.nhs.uk
Jack Newport carer
Crayford DA1 4SG
Josephine Venn-Treloar general practice assistant.
The Surgery, Welling DA16 2JZ
Competing interests: None declared.
1 Hughes JC, Robinson L, Volicer L. Specialist palliative care
in dementia. BMJ 2005;330:57-8. (8 January.)
Managing osteoarthritis of the
knee
Conclusions about use of NSAIDs are
misleading
Editor—The meta-analysis by Bjordal et al
of randomised controlled trials assessing the
efficacy of non-steroidal anti-inflammatory
drugs (NSAIDs) in osteoarthritic knee pain
is technically well done, but the authors’
conclusions are misleading.1 They assert that
the mean change in pain, as measured on a
visual analogue scale, over placebo was 10.1
mm (95% confidence interval 7.4 to 12.8)
and claim a non-relevant difference, since
the minimal clinically perceptible difference
was 9.7 mm.2
They mixed up the interpretations at
group and individual levels. Indeed, 9.7 is
the perceptible difference at the individual
level (a change lower than 9.7 mm would not
be perceived by the patient). However, the
10.1 mm estimate assessed by Bjordal et al
makes sense only at the group level.
To understand this multilevel interpreta-
tion better, we performed some calculations,
classifying patients as improved or not if
they achieved a change greater than 10.1
mm. Thus, hypothesising that in the placebo
group, the change equals 5+20 mm, 40.1%
of the placebo group patients would show
improvement (under the reasonable
assumption of a normal distribution of
change in pain on a visual analogue scale). A
treatment effect of 10.1 mm leads to a mean
change of 15.1 mm in the experimental
group, and 60.1% of patients would there-
fore show improvement. The number of
patients needed to treat is then estimated at
5.0. In the same way, if the difference in the
placebo group was 20±20 mm, 69.2% of
patients would show improvement in this
group and 84.3% in the experimental
group, and the number needed to treat
would then be 6.6. These examples show
that using the minimal clinically perceptible
difference to interpret changes at the group
level is inadequate: a small variation at the
group level does not mean no clinically rel-
evant change in the individuals of the group.
Florence Tubach assistant professor of epidemiology
florence.tubach@bch.ap-hop-paris.fr
P Ravaud professor of epidemiology,
INSERM U738; Groupe Hospitalier Bichat-Claude
Bernard (Assistance Publique—Hôpitaux de Paris);
Faculté Xavier Bichat (Université Paris 7), 46 rue
Henri Huchard, 75018 Paris, France
B Giraudeau assistant professor of biostatistics
INSERM CIC 202, Faculté de Médecine, 2 bis Bd
Tonnellé, 37032 Tours, France
Competing interests: None declared.
1 Bjordal JM, Ljunggren AE, Klovning A, Slordal L.
Non-steroidal anti-inflammatory drugs, including cyclo-
oxygenase-2 inhibitors, in osteoarthritic knee pain:
meta-analysis of randomised placebo controlled trials.BMJ
2004;329:1317. (4 December.)
2 Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seiden-
berg BC, Bellamy N. Minimal perceptible clinical improve-
ment with the western Ontario and McMaster universities
osteoarthritis index questionnaire and global assessments in
patients with osteoarthritis. J Rheumatol 2000;27:2635-41.
Authors’ reply
Editor—Tubach et al say that we misinter-
pret data by confusing group responses and
individual responses. They present hypo-
thetical calculations that supposedly show a
number needed to treat of 5-6.6 for
non-steroidal anti-inflammatory drugs
(NSAIDs) in osteoarthritis of the knee.
Their calculations are based on a
weighted mean difference of 10.1 mm on a
visual analogue scale from our analysis.
However, we showed that this group
response value was inflated by patient selec-
tion bias in a subgroup of trials. When this
subgroup of biased trials was removed from
analysis in our paper, the unbiased weighted
mean difference fell to 5.9 mm (3.8 to 7.9).
As a benchmark for response, Tubach et
al have selected what the inventors termed
the “minimally perceptible difference” at 9.7
mm on the visual analogue scale.1 A more
clinically relevant benchmark in knee osteo-
arthritis would be the “minimal clinically
important difference,” which corresponds to
19.9 mm on the scale.2 Using the unbiased
weighted mean difference and the latter
benchmark for treatment success, the result-
ing number needed to treat is in the 9-20
range.
Tubach et al make a point of the fact that
the occasional patient may experience
benefit from NSAID treatment. In our view,
it seems more relevant to question if patients
should be put at jeopardy for adverse effects
from oral NSAIDs when only a few of them
are likely to notice if their NSAID is replaced
by a placebo.
We stand by our conclusion that there is
a lack of evidence for clinically relevant
Letters
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effects from oral NSAIDs in knee osteo-
arthritis pain.
Jan M Bjordal research fellow
Jan.Bjordal@hib.no
Anne Elisabeth Ljunggren professor
Atle Klovning associate professor
Department of Public Health and Primary Health
Care, University of Bergen, 5018 Bergen, Norway
Lars Slørdal professor
Department of Laboratory Medicine, Children’s
and Women’s Health, Norwegian University of
Science and Technology, 7489 Trondheim, Norway
Competing interests: None declared.
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patients with osteoarthritis. J Rheumatol 2000;27:2635-41.
2 Tubach F, Ravaud P, Baron G, Falissard B, Logeart I,
Bellamy N, et al. Evaluation of clinically relevant changes
in patient reported outcomes in knee and hip osteoarthri-
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Rheum Dis 2005;64:29-33.
Holistic approach is important
Editor—The editorial by MacAuley on
managing osteoarthritis of the knee pro-
vides a welcome emphasis on the EULAR
recommended, holistic, multidisciplinary
approach to the condition.1
Excessive prescribing of non-steroidal
anti-inflammatory drugs in primary care
reflects the dependence of health profes-
sionals on “medicines based evidence”
rather than evidence based medicine and
the chronic underinvestment in other
approaches to osteoarthritis of the knee.2 No
reference was made to evidence of benefit of
weight loss programmes linked to exercise;
this is important, since increasing levels of
obesity and incident knee osteoarthritis are
strongly associated.3 Even relatively small
amounts of weight loss can reduce pain and
improve activity levels. At the point at which
knee replacement is appropriate, severely
disabled patients with a high body mass
index may be denied surgery.
MacAuley comments that physiotherapy
may delay decline. Community physiothera-
pists could have a central role in the
treatment of knee osteoarthritis, using moti-
vating clinical skills for individual or group
exercise programmes, gait retraining, tap-
ing, falls prevention, walking aids, footwear
advice, and pain relief techniques including
acupuncture and steroid injections.4 The
new cohort of NHS physiotherapy practi-
tioners with extended scope can independ-
ently assess, treat, and improve appropriate-
ness of referral to orthopaedic consultants.5
A physiotherapist may be a highly appropri-
ate lead musculoskeletal specialist in pri-
mary care, providing a functional approach
to treatment to minimise disability for
people with osteoarthritis of the knee and
overall offering far more in a consultation
than the average general practitioner.
The large community disability burden
and high knee pain referral rates to
orthopaedic specialists, warrant intervention
at a population level and an integrated care
pathway for osteoarthritis of the knee.3
Primary care trusts are in an ideal position
to develop expert initiatives for patients,
encourage the use of community sports
facilities, and promote the work of voluntary
bodies such as the Arthritis Research
Campaign, which provide excellent patient
information and professional education
resources.
Caroline A Mitchell general practitioner
Woodhouse Medical Centre, Sheffield S13 7LY
C.Mitchell@sheffield.ac.uk
Ade Adebajo consultant rheumatologist
Barnsley District General Hospital, Barnsley S75 2ED
Competing interests: None declared.
1 MacAuley D. Managing osteoarthritis of the knee. BMJ
2004;329:1300-1. (4 December.)
2 Dieppe P. Evidence-based medicine or medicines-based
evidence? Ann Rheum Dis 1998;57:385-6.
3 Underwood MR. Community management of knee pain
in older people: is knee pain the new back pain? Rheuma-
tology 2004;43:2-3.
4 Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma
JWJ, Dieppe P, et al. EULAR Recommendations 2003: an
evidence based approach to the management of knee
osteoarthritis: Report of a Task Force of the Standing
Committee for International Clinical Studies Including
Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:
1145-55.
5 Hattam P, Smeatham A. Evaluation of an orthopaedic
screening service in primary care. Br J Clin Governance
1999;4:45-9. 1999.
Glucosamine-chondroitin should be
prescribed by doctors
Editor—In his editorial on the manage-
ment of osteoarthritis of the knee MacAuley
recommended glucosamine-chondroitin as
an off prescription preparation.1 Can any-
one explain why it is usually recommended
so, despite evidence of efficacy that is as
good or better than most non-steroidal anti-
inflammatory drugs (NSAIDs), which cause
a huge burden of morbidity and mortality)?
Yet NSAIDs, and cleverly marketed vari-
ations of the theme, continue to be licensed
and adopted for NHS prescription for osteo-
arthritis, and I am sure will continue to do so
despite the debacle surrounding the cyclo-
oxygenase 2 inhibitors. Remember also
benoxaprofen 25 years ago.2
Most patients with osteoarthritis will
qualify for free prescriptions and are in the
age group with least income flexibility. Most
do not need surgery but are still suffering. I
understand that glucosamine is prescrib-
able, but rheumatologists and general
practitioners seem to advise patients to buy
their own—why? I fear that the background
to this is the huge threat to NSAID sales that
is posed by any form of help that patients
with osteoarthritis may receive from other
sources. But why spend on many expensive
NSAIDs, with no convincing overall benefit
to patients over cheaper alternatives (and
sometimes major harms), and not on
glucosamine-chondroitin?
Roger Chalmers full time NHS locum general
practitioner
Bury St Edmunds, Suffolk IP31 3TE
rachalmers@onetel.com
Competing interests: RC is concerned about the
damaging effect of drug companies’ influence on
NHS and doctors’ decisions in the interest of
patients.
1 MacAuley D. Managing osteoarthritis of the knee. BMJ
2004;329:1300-1. (4 December.)
2 Benoxaprofen. In: Sweetman SC, ed. Martindale: the
complete drug reference. 34th ed. London: Pharmaceutical
Press, 2005:21.1.
Opioids help manage pain in osteoarthritis
Editor—MacAuley raises an important
point about the poor long term manage-
ment of pain in osteoarthritis of the knee.1
A recent survey carried out by Arthritis
Care to assess the impact of osteoarthritis on
patients showed that 81% of the sample said
they experience constant pain and that when
their osteoarthritis is bad, 69% have difficulty
carrying out even the simplest of daily
household tasks.2 Exercise is undoubtedly of
benefit to patients with mild to moderate
osteoarthritis, so the priority of healthcare
professionals should be the symptomatic
relief of chronic pain. Along with paraceta-
mol and non-steroidal anti-inflammatory
drugs there is further ammunition for pain
relief. Opioids can and should be considered
in these patients. As stated by the Pain
Society,3 the primary effect of the appropri-
ate use of opioids in chronic pain is analgesia
that leads to improved function, sleep, and
reduced distress. Their use may also result in
reduced use of other analgesics.
With improved education of healthcare
professionals and the patient, opioid treat-
ment can be initiated and managed in
primary care through developing an indi-
vidualised treatment plan in discussion with
the patient. Doctors in general practice
should therefore recognise that appropriate
prescribing of opioids can offer a substantial
improvement in a patient’s quality of life.
Martin Johnson general practitioner
Ashville Medical Centre, Barnsley S70 3RJ
mjohnson@profiad.com
Competing interests: MJ has carried out consul-
tancy work with Napp Pharmaceuticals, Pfizer,
Janssen-Cilag.
1 MacAuley D. Managing osteoarthritis of the knee. BMJ
2004;329:1300-1. (4 December.)
2 Arthritis Care.OA nation: the most comprehensive UK report of
people with osteoarthritis. London: Arthritis Care, 2004
(http://oanation.arthritiscare.org.uk/90.0.html).
3 Consensus statement.Recommendations for the appropriate use
of opioids for persistent non-cancer pain. London: Pain Society,
2004 (www.britishpainsociety.org/pdf/opioids_doc_2004.
pdf).
United Kingdom back pain
exercise and manipulation (UK
BEAM) trial
Touch may have had non-specific effect,
among other things
Editor—I have three brief comments on the
United Kingdom back pain exercise and
manipulation (UK BEAM) trial.1
Firstly, the data are compatible with a
non-specific effect caused by touch: exercise
has a significantly positive effect on back pain
which can be enhanced by touch. If this “dev-
il’s advocate” view is correct, the effects have
little to do with spinal manipulation itself.
Secondly, which of the three profes-
sional groups (chiropractors, osteopaths,
physiotherapists) generated the largest
effect size is relevant. This might significantly
influence the referral pattern. A post-hoc
analysis might answer this question.
Lastly, the study monitored only serious
adverse effects. Data show that minor
Letters
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adverse effects occur in about 50% of
patients after spinal manipulation.2 Such
adverse events might then also influence
general practitioners’ referrals.
Edzard Ernst director
Complementary Medicine, Peninsula Medical
School, Exeter EX2 4NT
Edzard.Ernst@pms.ac.uk
Competing interests: None declared.
1 UK BEAM Trial Team. United Kingdom back pain
exercise and manipulation (UK BEAM) randomised trial:
effectiveness of physical treatments for back pain in
primary care. BMJ 2004;329:1377-81. (11 December.)
2 Stevinson C, Ernst E. Risks associated with spinal manipu-
lation. Am J Med 2002;112:566-70.
What happened to participants who were
not included in analysis?
Editor—The UK BEAM Trial Team has pro-
duced a broad piece of research that has
attempted to answer many questions about
managing chronic back pain all at the same
time.1 However, I find it difficult to under-
stand how any conclusions can be drawn
from the published results if 25% of the study
population were not included in the analysis
(23% at threemonths and 26% at 12months).
Knowing what happened to these
participants would be helpful because any
conclusions drawn from the remaining data
without an intention to treat analysis severely
weaken what is a brave piece of research.
Richard Tillett senior primary care physiotherapist,
Mid Devon Primary Care Trust
Blackdown Practice, Hemyock, Devon EX15 3SF
rtillett@breathe.com
Competing interests: None declared.
1 UK BEAM Trial Team. United Kingdom back pain
exercise and manipulation (UK BEAM) randomised trial:
effectiveness of physical treatments for back pain in
primary care. BMJ 2004;329:1377-81. (11 December.)
Is manipulation the most cost effective
addition to “best care”?
Editor—We are surprised by the conclu-
sions of the two papers by the UK BEAM
Trial Team.1 2 The authors compared three
interventions: manipulation, exercise, and
the combination of manipulation and
exercise. In the recently published European
guidelines for treatment of chronic low back
pain (www.backpaineurope.org) the trial is
rated as of high quality.3 However, the treat-
ment effects are small, and they are not
clinically significant.4
Surprisingly, there are no comparisons
between the treatments. So far as we can tell
from the information given in the papers,
simple Student’s t-tests do not show any sig-
nificant differences between exercise and
manipulation on Roland Morris or the
physical component scale of the SF-36. The
only significant difference is on the mental
component scale of the SF-36, manipulation
being significantly better than exercise at
three months.
It is, therefore, difficult to follow why the
authors claim that spinal manipulation is a
cost effective addition to “best care” for back
pain in general practice, and that manipula-
tion alone may give better value for money
than manipulation followed by exercise.
As we understand the papers, manipula-
tion and best care were of equal benefit
regarding clinical significance (Roland Mor-
ris), and there was no significant difference
between exercise and manipulation (Roland
Morris and SF-36 physical component).
Given that there is no clinical effect, we would
expect that the least expensive treatment
would be recommended. If any treatment
should be added on to best care, we think that
exercise would be the better choice because
of all the other health benefits.
Torill H Tveito research fellow
Torill.Tveito@psych.uib.no
Hege R Eriksen professor
Department of Biological and Medical Psychology,
University of Bergen, Jonas Liesvei 91, N-5009
Bergen, Norway
Competing interests: None declared.
1 UK BEAM Trial Team. United Kingdom back pain
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2 UK BEAM Trial Team. United Kingdom back pain
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3 European Commission Research Directorate General.
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Manipulation alone costs more than
other options so why is it recommended?
Editor—It is not clear why the UK Beam
Trial Team recommends manipulation
alone for back pain because it costs more
per quality adjusted life year (QALY) than
exercise and manipulation combined and
even slightly more than exercise alone.1 The
average effect of exercise and manipulation
combined is also larger than the other two in
absolute terms.
Timothy R Church associate professor
University of Minnesota, Minneapolis, MN 55455, USA
trc@cccs.umn.edu
Competing interests: None declared.
1 UK BEAM Trial Team. United Kingdom back pain
exercise and manipulation (UK BEAM) randomised trial:
cost effectiveness of physical treatments for back pain in
primary care. BMJ 2004;329:1381-5. (11 December.)
Authors’ reply
Editor—Ernst is correct that the beneficial
effects UK BEAM found for manipulation
could be a non-specific effect. This was a prag-
matic study testing a package of manipulatory
treatment, not an explanatory study seeking to
assess the effect of manipulation itself.
All the manipulation practitioners used
a common treatment package agreed by the
three professional groups.1 Any compari-
sons between the professions would be
underpowered and, because participants
were allocated to therapists nearest their
home, non-randomised. Such a comparison
was specifically precluded when the profes-
sions agreed to the treatment package.
Ernst’s data do not support the assertion
that adverse effects occur after 50% of spinal
manipulations.2 Any such effects are usually
minor and short lived. Set against the
positive effect of being able to do one more
daily activity one year later we would not
expect this to influence general practition-
ers’ referral decisions.
Tilett is concerned about our follow up
rate. For a large nationwide trial of this
nature it was, if anything, better than might
be expected. Since the characteristics of
those lost to follow up were consistent across
all randomised groups, and the largest
difference in follow up rates between
treatment and control groups was only
4.1%, little risk of bias exists. Our sensitivity
analysis, using the last observation carried
forward, does not change our findings.
Tveito and Eriksen argue that we should
recommend adding exercise to “best care”
even though exercise did not produce a sta-
tistically significant benefit at one year and
its overall cost is greater than either
manipulation or best care. Our data do not
support the premise that manipulation and
exercise are equally effective.3 The average
benefits of the BEAM interventions for indi-
vidual patients are small. However, at a
population level, our manipulation or
combined packages produce an overall ben-
efit at modest cost, as other healthcare use
fell during the following year.
Church is unclear on our health eco-
nomic conclusions. We are not recommend-
ing manipulation as the only treatment
option. Instead we are saying that the UK
BEAM manipulation package is the best
strategy should the decision maker be willing
to pay £8700 or more for each additional
quality adjusted life year (QALY). If a decision
maker is willing to pay > £3800 and < £8700
per additional QALY, combined treatment is
the best strategy.When the decision maker is
willing to pay < £3800 per QALY general
practitioner care is the best strategy.
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